An in-depth look to TAIGEN BIOPHARMACEUTICALS HLDGS LTD operating, investing, and financing activities

4157 free cash flow for Q3 24 is -29.78 M TWD. For 2023, 4157 free cash flow was 16.85 M TWD and operating cash flow was 20.74 M TWD.